Cargando…

A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters

Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those seconda...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jui-Wen, Hung, Jen-Lin, Takeuchi, Masaru, Shieh, Po-Chuen, Horng, Chi-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695351/
https://www.ncbi.nlm.nih.gov/pubmed/36431188
http://dx.doi.org/10.3390/jcm11226710
_version_ 1784838035504889856
author Ma, Jui-Wen
Hung, Jen-Lin
Takeuchi, Masaru
Shieh, Po-Chuen
Horng, Chi-Ting
author_facet Ma, Jui-Wen
Hung, Jen-Lin
Takeuchi, Masaru
Shieh, Po-Chuen
Horng, Chi-Ting
author_sort Ma, Jui-Wen
collection PubMed
description Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those secondary to vitreous hemorrhage (VH). Methods: 224 patients with monocular symptomatic vitreous opacities (SVOs) were recruited between September and December 2017 and received oral supplementation of MFEs (190 mg bromelain, 95 mg papain, and 95 mg ficin) for 3 months in a double-blind clinical trial. Participants were divided according to the etiology of the SVOs, spontaneous (experiment 1) versus VH (experiment 2), and then randomly assigned into four treatments groups: one group received oral vitamin C, as a placebo; and the other 3 groups received 1 capsule per day (low dose), 2 capsules per day (middle dose), or 3 capsules per day (high dose) of MFEs. The number of SVOs was determined at baseline and then 1, 2, and 3 months after initiating treatment. Further, in cases secondary to VH, the changes in corrected distance visual acuity (CDVA) were assessed after 3 months. Second, we compared the free radical scavenging capabilities of each substance: vitamin C, bromelain, papain, ficin, and MFEs (combination of bromelain, papain, and ficin) by DDPH assay. Finally, SVOs-related symptoms and satisfaction with the treatments were evaluated at the last follow-up visit Results: In experiment 1, the disappearance rate of SVOs was 55%, 62.5%, and 70% after taking 1, 2, and 3 capsules daily, respectively (total p < 0.001), in a dose-dependent manner. In experiment 2, the disappearance rate of VH-induced SVOs was 18%, 25%, and 56% (p < 0.001) after 1, 2, and 3 capsules of the supplement daily, respectively. Additionally, the patients’ vision elevated from 0.63LogMAR to 0.19LogMAR (p = 0.008). Conclusions: A pharmacological approach using a high dose of oral supplementation with MFEs (bromelain, papain, and ficin) was effective in reducing vitreous opacities, even after intraocular hemorrhage. Furthermore, pharmacologic vitreolysis with MFEs supplementation showed high patient satisfaction, and also improved CDVA in patients with vitreous hemorrhage-induced floaters
format Online
Article
Text
id pubmed-9695351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96953512022-11-26 A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters Ma, Jui-Wen Hung, Jen-Lin Takeuchi, Masaru Shieh, Po-Chuen Horng, Chi-Ting J Clin Med Article Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those secondary to vitreous hemorrhage (VH). Methods: 224 patients with monocular symptomatic vitreous opacities (SVOs) were recruited between September and December 2017 and received oral supplementation of MFEs (190 mg bromelain, 95 mg papain, and 95 mg ficin) for 3 months in a double-blind clinical trial. Participants were divided according to the etiology of the SVOs, spontaneous (experiment 1) versus VH (experiment 2), and then randomly assigned into four treatments groups: one group received oral vitamin C, as a placebo; and the other 3 groups received 1 capsule per day (low dose), 2 capsules per day (middle dose), or 3 capsules per day (high dose) of MFEs. The number of SVOs was determined at baseline and then 1, 2, and 3 months after initiating treatment. Further, in cases secondary to VH, the changes in corrected distance visual acuity (CDVA) were assessed after 3 months. Second, we compared the free radical scavenging capabilities of each substance: vitamin C, bromelain, papain, ficin, and MFEs (combination of bromelain, papain, and ficin) by DDPH assay. Finally, SVOs-related symptoms and satisfaction with the treatments were evaluated at the last follow-up visit Results: In experiment 1, the disappearance rate of SVOs was 55%, 62.5%, and 70% after taking 1, 2, and 3 capsules daily, respectively (total p < 0.001), in a dose-dependent manner. In experiment 2, the disappearance rate of VH-induced SVOs was 18%, 25%, and 56% (p < 0.001) after 1, 2, and 3 capsules of the supplement daily, respectively. Additionally, the patients’ vision elevated from 0.63LogMAR to 0.19LogMAR (p = 0.008). Conclusions: A pharmacological approach using a high dose of oral supplementation with MFEs (bromelain, papain, and ficin) was effective in reducing vitreous opacities, even after intraocular hemorrhage. Furthermore, pharmacologic vitreolysis with MFEs supplementation showed high patient satisfaction, and also improved CDVA in patients with vitreous hemorrhage-induced floaters MDPI 2022-11-13 /pmc/articles/PMC9695351/ /pubmed/36431188 http://dx.doi.org/10.3390/jcm11226710 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ma, Jui-Wen
Hung, Jen-Lin
Takeuchi, Masaru
Shieh, Po-Chuen
Horng, Chi-Ting
A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title_full A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title_fullStr A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title_full_unstemmed A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title_short A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
title_sort new pharmacological vitreolysis through the supplement of mixed fruit enzymes for patients with ocular floaters or vitreous hemorrhage-induced floaters
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695351/
https://www.ncbi.nlm.nih.gov/pubmed/36431188
http://dx.doi.org/10.3390/jcm11226710
work_keys_str_mv AT majuiwen anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT hungjenlin anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT takeuchimasaru anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT shiehpochuen anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT horngchiting anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT majuiwen newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT hungjenlin newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT takeuchimasaru newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT shiehpochuen newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters
AT horngchiting newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters